The deal echoes that of fellow German vaccine developer BioNTech with US giant Pfizer, whose jab became the first to be approved in the European Union.
“Coupled with the unparalleled demand, these products will help to develop Covid-19 vaccines into a multibillion-dollar commercial opportunity,” it stated.
France's performance since its drive started on December 27, compares with hundreds of thousands given the vaccine in Germany and over 1.3 million in the UK, which started earlier.
China is determined to control the origin story of the virus, which has killed more than 1.8 million people around the world and laid waste to global economies.
Britain began its third COVID-19 lockdown on Tuesday with the government calling for one last major national effort to defeat the spread of a virus that has infected an estimated one in 50 citizens before mass vaccinations turn the tide.
Britain has been among the countries worst-hit by COVID-19, with the second highest death toll in Europe and an economy that suffered the sharpest contraction of any in the Group of Seven during the first wave of infections last spring.
Malpass said the Bank expected to bring the first country vaccine financing plans to its board for approval shortly, but did not identify the countries involved.